Countries with lower HIV prevalence have lower ART coverage
22 March 2016. Related: Conference reports, Antiretrovirals, Treatment access.
Antiretrovirals
Nigerian herbal medicines widely used by HIV positive people can contain antiretrovirals
22 March 2016. Related: Conference reports, Antiretrovirals.
EU adopts positive opinion on dual formulation of F/TAF
22 March 2016. Related: Antiretrovirals.
New TAF-containing fixed dose combination approved in the US
22 March 2016. Related: Antiretrovirals.
BMS sells pipeline compounds to ViiV Healthcare
1 February 2016. Related: Antiretrovirals.
EU provide positive approval for generic lopinavir/ritonavir
1 February 2016. Related: Antiretrovirals.
Further results using dolutegravir monotherapy: urgent need for controlled studies
1 February 2016. Related: Antiretrovirals, Treatment strategies.
Potential economic impact of dolutegravir/3TC dual therapy
1 February 2016. Related: Antiretrovirals, Treatment strategies.
Remarkable results with dolutegravir monotherapy
1 December 2015. Related: Conference reports, Antiretrovirals, Vaccines and microbicides.
First-line ART with dolutegravir plus 3TC: 24-week early results
1 December 2015. Related: Conference reports, Antiretrovirals, Treatment strategies.
Achieving viral suppression with HIV multi-drug resistance: peg-interferon and valaciclovir as part of rescue therapy
1 December 2015. Related: Conference reports, Antiretrovirals, Treatment strategies, Drug resistance.
Substituting lopinavir/ritonavir with efavirenz in children on stable ART
1 December 2015. Related: Conference reports, Antiretrovirals, Paediatric care.
Tenofovir alafenamide (TAF) approved – but only as part of a fixed dose combination
1 December 2015. Related: Antiretrovirals.
No transmission of integrase-resistant HIV seen in California cohort
1 October 2015. Related: Conference reports, Antiretrovirals, HIV prevention and transmission, Drug resistance.
Doubled hypogonadism rate in middle-aged men with HIV: fat is a factor
1 October 2015. Related: Conference reports, Antiretrovirals, Side effects.
Reducing efavirenz dose is unlikely to overcome interaction with levonorgestrel
1 October 2015. Related: Conference reports, Antiretrovirals, Women's health, Pregnancy, PK and drug interactions.
Doravirine and cabotegravir do not affect the pharmacokinetics of oral contraceptives
1 October 2015. Related: Conference reports, Antiretrovirals, Women's health, PK and drug interactions.
Dolutegravir placental transfer moderate in ex vivo model
1 October 2015. Related: Conference reports, Antiretrovirals, Pregnancy, PK and drug interactions.
FDA approve additional weight band dosing for children using atazanavir powder
1 October 2015. Related: Antiretrovirals, Paediatric care.
Four reasons IAS 2015 will be a milestone HIV conference: a personal view
1 August 2015. Related: Conference reports, Antiretrovirals, Treatment strategies, HIV prevention and transmission.
Starting HIV treatment at high CD4 counts protects against both AIDS and non-AIDS events: overall and in subgroup analyses of START study
1 August 2015. Related: Conference reports, Antiretrovirals, Treatment strategies.
Pipeline ARVs at IAS 2015: doravirine, BMS-955176 and BMS-663068
1 August 2015. Related: Conference reports, Antiretrovirals.
Rapid implementation of the 2013 WHO ART guidelines
1 August 2015. Related: Conference reports, Antiretrovirals, Guidelines.
Rilpivirine/FTC/TAF becomes the third TAF-based fixed dose combination submitted for US approval
1 August 2015. Related: Antiretrovirals.
The antiretroviral pipeline 2015
17 July 2015. Related: Pipeline report, Antiretrovirals.
Fit for purpose: antiretroviral treatment optimisation 2015
17 July 2015. Related: Pipeline report, Fit for purpose, Antiretrovirals.
The Pediatric Antiretroviral Pipeline
17 July 2015. Related: Pipeline report, Antiretrovirals, Paediatric care.
BHIVA pregnancy audit 2013 to 2014
1 June 2015. Related: Conference reports, Antiretrovirals, Pregnancy.
Primary HIV infection and early use of ART
1 June 2015. Related: Conference reports, Antiretrovirals.
Rectal STIs and viral load in HIV positive men on and off ART
1 June 2015. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.
Other short reports from BHIVA:
1 June 2015. Related: Conference reports, Antiretrovirals, Paediatric care, Basic science and immunology.
Elvitegravir in children and adolescents
1 June 2015. Related: Conference reports, Antiretrovirals, Paediatric care, PK and drug interactions.
PK of ARVs in pregnancy: rilpivirine, etravirine and raltegravir
1 June 2015. Related: Conference reports, Antiretrovirals, Pregnancy, PK and drug interactions.
Pharmacokinetics in pregnancy: darunavir/r and etravirine
1 June 2015. Related: Conference reports, Antiretrovirals, Pregnancy, PK and drug interactions.
Low prolactin and high 20alpha-HSD might contribute to ART-associated progesterone deficits in pregnancy
1 June 2015. Related: Conference reports, Antiretrovirals, Women's health, Pregnancy.
Pregnancy rates among women using ART and hormonal contraceptives in Kenya
1 June 2015. Related: Conference reports, Antiretrovirals, Pregnancy.
Gender difference in virological response to ART
1 June 2015. Related: Conference reports, Antiretrovirals, Women's health.
Generic dolutegravir submitted to FDA for tentative approval
1 June 2015. Related: Antiretrovirals, Treatment access.
EMA approves coformulated atazanavir/cobicistat
1 June 2015. Related: Antiretrovirals.
Dual F/TAF formulation under evaluation by EMA
1 June 2015. Related: Antiretrovirals.
Pipeline ART: tenofovir alafenamide (TAF)
24 March 2015. Related: Conference reports, Antiretrovirals.
Pipeline ART: maturation inhibitors and an attachment inhibitor
24 March 2015. Related: Conference reports, Antiretrovirals.
PrEP reduced HIV risk by at least 86% in PROUD: no transmissions likely from people taking meds
24 March 2015. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.
FDA approves fixed dose darunavir/cobicistat
24 March 2015. Related: Antiretrovirals.
FDA approves fixed dose atazanavir/cobicistat
24 March 2015. Related: Antiretrovirals.
FDA approves fixed dose raltegravir/3TC formulation: Merck holds back from marketing in US
24 March 2015. Related: Antiretrovirals.
Dolutegravir and Truimeq approved in England
29 January 2015. Related: Antiretrovirals.
London prescribing guidelines updated to include dolutegravir and Triumeq
29 January 2015. Related: Antiretrovirals.
Adequate cerebrospinal fluid exposure of efavirenz when dosed at 400 mg
29 January 2015. Related: Antiretrovirals.
Savings to the NHS predicted from switching to generic antiretrovirals
1 December 2014. Related: Conference reports, Antiretrovirals, Treatment access.
Lower dose efavirenz effective in two studies
1 December 2014. Related: Conference reports, Antiretrovirals.
Should tenofovir dose be 200 – 250 mg when used with protease inhibitors?
1 December 2014. Related: Conference reports, Antiretrovirals.
3TC inferior to FTC in Dutch cohort but interchangeable in other studies
1 December 2014. Related: Conference reports, Antiretrovirals.
Suicide not associated with efavirenz use in the D:A:D cohort study
1 December 2014. Related: Conference reports, Antiretrovirals, Side effects.
Efavirenz decreases exposure to hormonal contraceptive implant
1 December 2014. Related: Conference reports, Antiretrovirals, Side effects.
Increased risk of ART-related hepatotoxicity in HIV positive pregnant women
1 December 2014. Related: Conference reports, Antiretrovirals, Pregnancy, Side effects.
Darunavir pharmacokinetics in pregnancy and postpartum
1 December 2014. Related: Conference reports, Antiretrovirals, Pregnancy.
Efavirenz-associated gynaecomastia reported to the national HIV and TB healthcare workers hotline in South Africa
1 December 2014. Related: Conference reports, Antiretrovirals, Side effects.
Infants start ART too late but improvement over time in Southern Africa
1 December 2014. Related: Conference reports, Antiretrovirals, Paediatric care.
Pregnancy a risk factor for poor antiretroviral treatment outcomes in South African adolescents
1 December 2014. Related: Conference reports, Antiretrovirals, Women's health, Pregnancy.
Equivalent efficacy with lower dose darunavir
1 December 2014. Related: Antiretrovirals, PK and drug interactions.
Antiretroviral studies at ICAAC 2014: darunavir-based FDC with TAF, cobicistat, doravirine, Stribild and gel formulation PrEP
1 October 2014. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.
Switch from efavirenz to rilpivirine quells CNS toxicity, improves sleep
1 October 2014. Related: Conference reports, Antiretrovirals.
HIV persists in lung macrophages of people on suppressive ART
1 October 2014. Related: Conference reports, Antiretrovirals, Cure-related research.
Risk of CVD or type-2 diabetes according to change in BMI after starting ART
1 October 2014. Related: Conference reports, Antiretrovirals, Side effects.